Great — below is a concise, evidence-backed briefing on the U.S. Durable Medical Equipment (DME) market with company references and available values, organized under the headings you asked for. I cite primary sources for the most important figures and policy items.

This versatile research report is presenting crucial details on market relevant information, harping on ample minute details encompassing a multi-dimensional market that collectively maneuver growth in the global US Durable Medical Equipment market.

This holistic report presented by the report is also determined to cater to all the market specific information and a take on business analysis and key growth steering best industry practices that optimize million-dollar opportunities amidst staggering competition in US Durable Medical Equipment market.

Read complete report at: https://www.thebrainyinsights.com/report/us-durable-medical-equipment-market-13510

Company references (major players) — with values / evidence

Note: many DME suppliers are large diversified healthcare companies; publicly disclosed company revenue is often available but product-level (DME-only) revenue is rarely broken out in public filings. I list company revenues where recent public figures exist and note when only company-level revenue is available.

• Medline Industries (private) — one of the largest U.S. medical suppliers / DME distributors. Reported ~$13.5B revenue in H1 2025 and public reporting/press estimates place annual sales at ~$23B (company preparing large U.S. IPO).

• ResMed, Inc. — major supplier of sleep/respiratory equipment (a key DME category). FY2025 revenue: ~$5.1B (company press release). 

• Philips (Health technology) — large provider of hospital and home respiratory/monitoring equipment. 2024 sales: €18.0B (company annual report). 

• Invacare Corporation — specialist in mobility and home care equipment (wheelchairs, scooters, support surfaces). Public filings and historical reports show multi-hundred-million revenue run-rate; full company revenue series available in filings.

• Drive DeVilbiss / Drive Medical (private) — prominent in respiratory, mobility and home medical equipment; company materials and industry data give regional revenue estimates (private).

• Other important participants: McKesson, Cardinal Health, Owens & Minor, Hillrom (Baxter/Hillrom assets), Philips, Abbott, Becton Dickinson (BD), Fisher & Paykel, GE Healthcare, Smiths Medical — large distributors/manufacturers who either sell DME or provide complementary equipment & logistics. (Company revenues vary widely; cited above where publicly reported.)

Market values — headline numbers (U.S.)

• U.S. market size (2024): multiple market reports cluster around ~USD 63–67 billion for 2024 (Grand View Research: USD 66.81B in 2024).

• Forecast / CAGR: consensus forecasts ~~5–6.5% CAGR (typical publisher ranges: 5.03%–6.44% depending on horizon). Example: Grand View projects 5.61% CAGR (2025–2030).

Recent Development

• Medicare DMEPOS policy & competitive bidding updates (CMS has been actively revising the DMEPOS Competitive Bidding Program and issued transitional/gap notices; proposed rule changes in 2025 target pricing, accreditation and prior authorization). This regulatory activity materially affects supplier margins and procurement. 

• Major consolidation & IPO activity: Medline’s IPO plans and private-equity ownership events are reshaping distribution concentration and capital available for growth.

• Technology & home-care focus: growth of home respiratory (including OSA/BiPAP/CPAP), mobility aids, remote patient monitoring devices and connected DME. ResMed and Philips reported strong device trends and revenue growth in respiratory/remote care segments.

Drivers

• Aging U.S. population & chronic disease prevalence (higher need for oxygen, mobility aids, supports).

• Shift to home care & telehealth (more procedures and care outside hospitals; remote monitoring + home DME).

• Technological innovation (smart devices, cloud-connected monitoring, improved portable respiratory devices).

Restraints

• Medicare reimbursement pressure & DMEPOS competitive bidding — pricing pressure from CMS programs and payer contracting reduces margins. Regulatory uncertainty (rule changes/proposals) can slow investments.

• Consolidation of GPOs / large distributors leads to negotiating pressure on smaller suppliers.

Regional segmentation analysis (within U.S.)

• High demand / large share: urban & suburban markets with older populations—Northeast and Midwest have high DME utilization for home health; California, Texas, Florida show large absolute volumes due to population. (Market reports typically break out by census divisions—national concentration around states with large Medicare populations.) 

• Fastest growth pockets: regions with expanding home health agencies, rural telehealth adoption, and higher incidence of chronic respiratory disease (e.g., parts of the Southeast).

Emerging Trends

• Connected/remote-monitoring DME (devices feeding data to care teams/EHRs).

• Shift to outpatient & home-first models (portable oxygen, home ventilators, mobility aids).

• Supplier consolidation & vertical integration (distribution + manufacturing combos; large private firms preparing IPOs).

Top Use Cases

• Sleep & respiratory care — CPAP/BiPAP/oxygen concentrators (ResMed, Philips).

• Mobility aids & seating — wheelchairs, scooters, walkers (Invacare, Drive Medical).

• Home infusion / enteral feeding / monitoring — used by home health providers and specialty pharmacies.

• Support surfaces & patient transfer equipment — for pressure injury prevention and hospital/home use.

Major Challenges

• Reimbursement uncertainty (CMS rule changes, competitive bidding, prior authorization proposals).

• Proving clinical value & cost-effectiveness for advanced/connected devices to justify higher prices.

• Supply chain & tariff impacts (global component sourcing and manufacturing costs—reported by major manufacturers).

Attractive Opportunities

• Upside in home-based care & post-acute services (devices and services tailored for home).

• Value-add services (managed services, monitoring subscriptions, bundle offerings to payers/ASCs).

• Emerging product premiumization—connected DME and advanced respiratory devices attract premium pricing if clinical outcomes data is strong.

Key factors of market expansion

1. Demographics & chronic disease prevalence (aging population).

2. Home-health / outpatient care shift and telehealth integration.

3. Regulatory & reimbursement environment (CMS policy will either accelerate or constrain growth depending on outcomes of rulemaking).

4. Innovation in device connectivity and remote monitoring, enabling new service models and recurring revenue.

If you want company-level tables (I can produce immediately)

I can produce one of the following right now (pick one and I’ll generate it immediately with sources):

A. Table: major companies → latest available company revenue (most recent fiscal year) → primary DME product categories they sell → source links.
B. Table: competitive landscape with estimated U.S. DME market shares (by vendor) where available + source notes (will rely on industry reports / estimations).
C. Custom extract: pull all CMS DMEPOS policy actions/Proposed Rules since 2023 that affect suppliers (timeline + expected impact).